Latest Content

Oncology dietitian Gabrielle Raucci explores the role of creatine in cancer care, highlighting when to use it and risks during active treatment.

The FDA has approved perioperative pembrolizumab and enfortumab vedotin for adult patients with muscle-invasive bladder cancer.

As ivermectin interest surges via social media, oncology nurses must balance empathetic communication with evidence-based safety and clinical caution.

A study reveals only 18.3% of young adults with advanced cancer receive palliative care, highlighting a critical gap for oncology nurses to address.

New research identifies treatment initiation thresholds that impact 3-year metastasis risk in colorectal cancer patients across distinct pathways.

In the phase 3 RASolute 302 trial, oral KRAS inhibitor daraxonrasib nearly doubled median overall survival to 13.2 months in pancreatic cancer.

Oncology nurses discuss managing lung cancer as a chronic disease, addressing long-term symptoms, financial toxicity, and psychosocial care.

The FDA approved zidesamtinib for metastatic ROS1-positive NSCLC following prior kinase inhibitor therapy, offering hope for patients with resistance.

A Neurology study reveals breast cancer survivors have a high ischemic stroke risk within one year of diagnosis, linked to specific treatment regimens.

NYU Langone experts discuss multidisciplinary care, diagnostic challenges, and nursing's role in treating rare bone and soft tissue sarcomas.

A 10-year study of 3,477 patients reveals focal therapy offers high survival and low metastasis for localized prostate cancer with few side effects.

Simone Payette-Capone, RN, discusses balancing protocol with patient care, managing GU trial logistics, and the research nurse's role as a "detective."

NATCO Pharma receives tentative U.S. FDA approval for a generic version of the PARP inhibitor olaparib (Lynparza) for oncology indications.